Skip to main content
Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
3.060
+0.170 (5.88%)
At close: Apr 28, 2026, 4:00 PM EDT
3.070
+0.010 (0.33%)
After-hours: Apr 28, 2026, 6:01 PM EDT

Editas Medicine Revenue

In the year 2025, Editas Medicine had annual revenue of $40.52M with 25.39% growth. Editas Medicine had revenue of $24.74M in the quarter ending December 31, 2025, a decrease of -19.16%.

Revenue (ttm)
$40.52M
Revenue Growth
+25.39%
P/S Ratio
7.17
Revenue / Employee
$465,747
Employees
87
Market Cap
299.49M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202540.52M8.21M25.39%
Dec 31, 202432.31M-45.81M-58.64%
Dec 31, 202378.12M58.41M296.32%
Dec 31, 202219.71M-5.83M-22.83%
Dec 31, 202125.54M-65.19M-71.85%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Cellectis 79.59M
Compugen 72.76M
Coherus Oncology 42.17M
C4 Therapeutics 35.95M
Zentalis Pharmaceuticals 26.87M
LENZ Therapeutics 19.09M
AC Immune 4.51M
Revenue Rankings

EDIT News

More News